4-(苄氧基)-3-氟苯酚 | 81228-25-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 4-(苄氧基)-3-氟苯酚
• 中文别名: 4-苄氧基-3-氟苯酚
• 英文名称: 4-(benzyloxy)-3-fluorophenol
• 英文别名: 3-fluoro-4-phenylmethoxyphenol
• CAS: 81228-25-3
• 化学式: C₁₃H₁₁FO₂
• 分子量: 218.228
• InChiKey: GYIIGCADGAQVFT-UHFFFAOYSA-N

物化性质

• 熔点：
  80-82 °C
• 沸点：
  372.1±27.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2909500000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  4-(苄氧基)-3-氟苯酚 在 palladium on activated charcoal 氢气 、 硝酸 、 sodium hydride 、 溶剂黄146 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 20.0~85.0 ℃ 、101.33 kPa 条件下， 反应 130.17h， 生成 4-(3-fluoro-4-hydroxy-5-nitrophenoxy)-pyridine-2-carboxylic acid methylamide
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase Inhibitors

  摘要：

  Inhibition of the VEGF signaling pathway has become a valuable approach in the treatment of cancers. Guided by X-ray crystallography and molecular modeling, a series of 2-aminobenzimidazoles and 2-aminobenzoxazoles were identified as potent inhibitors of VEGFR-2 (KDR) in both enzymatic and HUVEC cellular proliferation assays. In this report we describe the synthesis and structure-activity relationship of a series of 2-aminobenzimidazoles and benzoxazoles, culminating in the identification of benzoxazole 22 as a potent and selective VEGFR-2 inhibitor displaying a good pharmacokinetic profile. Compound 22 demonstrated efficacy in both the murine matrigel model for vascular permeability (79% inhibition observed at 100 mg/kg) and the rat corneal angiogenesis model (ED(50) = 16.3 mg/kg).

  DOI：

  10.1021/jm070034i
• 作为产物：
  描述：

  Acetic acid 4-benzyloxy-3-fluoro-phenyl ester 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 4-(苄氧基)-3-氟苯酚
  参考文献：
  名称：

  .beta.1-Selective adrenoceptor antagonists. 2. 4-Ether-linked phenoxypropanolamines

  摘要：

  A series of 4-substituted phenoxypropanolamines was prepared and examined for beta-adrenoceptor activity. Some of the compounds, especially the [4-[2-[[2-(4-fluorophenyl)ethyl] oxy]ethoxy]phenoxy]propanolamines (14, 15, and 24), showed potent beta 1-blockade with virtually no beta 2-blockade at doses over a 1000 times greater. The compounds also possessed partial agonist activity. Structure-activity relationships are discussed, and conclusions are drawn about the binding sites on beta-adrenoceptors.

  DOI：

  10.1021/jm00365a005

文献信息

• INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
  申请人：ECKHARDT Matthias

  公开号：US20140163025A1

  公开（公告）日：2014-06-12

  The present invention relates to compounds of general formula I, wherein the groups (Het)Ar and R 1 are defined as in claim 1 , which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式I的化合物， 其中基团(Het)Ar和R1如权利要求1所定义， 具有有价值的药理特性，特别是结合GPR40受体并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• [EN] NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS<br/>[FR] NOUVEAUX ACIDES INDANYLOXYDIHYDROBENZOFURANYLACÉTIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014086712A1

  公开（公告）日：2014-06-12

  The present invention relates to compounds of general formula I, wherein the groups (Het)Ar and R1 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式I的化合物，其中基团(Het)Ar和R1的定义如权利要求1中所述，具有有价值的药理特性，特别是与GPR40受体结合并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• GPR119 Receptor Agonists
  申请人：Erickson Shawn David

  公开号：US20090286812A1

  公开（公告）日：2009-11-19

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

  提供以下公式(I)的化合物： 以及可药用的接受盐，其中取代基如说明书中所披露。这些化合物以及含有它们的药物组合物可用于治疗代谢性疾病和障碍，例如，2型糖尿病。
• [EN] FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS<br/>[FR] AZOLES FUSIONNES TELS QUE BENZIMIDAZOLES, BENZOXAZOLES ET BENZOTHIAZLES 2,5-DISUBSTITUES COMME INHIBITEURS DE KINASE
  申请人：AMGEN INC

  公开号：WO2004085425A1

  公开（公告）日：2004-10-07

  The invention relates to compounds of the formulae (I) to (III) wherein the substituents are as defined in the specification. These compounds have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Accordingly, the compounds of the formulae (I) to (III) would be useful in the prevention and treatment of angiogenesis related disorders, ophthalmological conditions, proliferative diseases, inflammatory diseases, and other pathological conditions as described in the specification.

  这项发明涉及式(I)至(III)的化合物，其中取代基如规范中所定义。这些化合物具有激酶抑制活性，如VEGFR/KDR抑制活性。因此，式(I)至(III)的化合物在预防和治疗与血管生成相关的疾病、眼科疾病、增生性疾病、炎症性疾病以及规范中描述的其他病理状况中将会有用。
• Fully Automated Radiosynthesis of [¹¹C]Guanidines for Cardiac PET Imaging
  作者：Austin Y. Zhao、Allen F. Brooks、David M. Raffel、Jenelle Stauff、Janna Arteaga、Peter J. H. Scott、Xia Shao

  DOI：10.1021/acsmedchemlett.0c00479

  日期：2020.11.12

  challenging, and historical methods lack compatibility with modern automated radiochemistry synthesis platforms and current Good Manufacturing Practice (cGMP) requirements. To address this challenge, we report a new automated method for radiolabeling guanidines with carbon-11. The method was used to prepare a series of [11C]guanidines in good radiochemical yield (8–76% by radio-HPLC) and was found to have broad

  放射性标记的胍如间碘苄基胍(MIBG) 在核医学中用作诊断显像剂和放射治疗剂，多年来，已经开发了许多将放射性核素掺入胍中的方法。在开发用于心脏交感神经密度的新型正电子发射断层扫描 (PET) 放射性示踪剂的项目中，我们有理由准备 [ 11]C]3F-PHPOG。然而，很快就发现用碳 11 对胍支架进行放射性标记仍然具有挑战性，而且历史方法缺乏与现代自动放射化学合成平台和当前良好生产规范 (cGMP) 要求的兼容性。为了应对这一挑战，我们报告了一种用碳 11 对胍进行放射性标记的新自动化方法。该方法用于制备一系列具有良好放射化学产率（放射性 HPLC 为 8-76%）的 [ 11 C] 胍，并发现其具有广泛的底物范围和对未保护的 OH 和 NH 官能团的耐受性。该方法用于合成[ 11C]3F-PHPOG 用于临床前成像，以及放射性示踪剂临床前使用的适用性通过新西兰白兔的初步心脏 PET 得到证明，该